<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654069</url>
  </required_header>
  <id_info>
    <org_study_id>AP-ADF-105</org_study_id>
    <nct_id>NCT00654069</nct_id>
  </id_info>
  <brief_title>Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Repeat-dose Study of the Safety and Efficacy of Acuroc Tablets Following Bunionectomy Surgery in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acura Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acura Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oxycodone HCl and niacin are effective in
      the treatment of pain following bunionectomy surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase III, randomized, double blind, placebo controlled, multicenter, repeat dose
      study of the safety and efficacy of 2 dose levels of Acurox™ Tablets versus placebo for the
      treatment of moderate to severe postoperative pain following bunionectomy surgery.

      Patients underwent a primary unilateral first metatarsal bunionectomy with or without
      ipsilateral hammer toe repair during standardized local anesthesia with intravenous (IV)
      sedation. Eligible patients who reported moderate or severe pain within 6 hours after surgery
      entered the Treatment Phase and were randomized to 1 of 3 double blind treatments: placebo
      tablets or 1 of 2 dose levels of Acurox™ Tablets (ocyxcodone HCl/niacin). The Treatment Phase
      continued with study medication every 6 hours (irrespective of rescue medication use) for 48
      hours (8 doses of study medication). Toradol (ketorolac tromethamine) was available as a
      rescue medication upon request.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPID48</measure>
    <time_frame>48 hours</time_frame>
    <description>Time weighted Sum of Pain Intensity Differences over the first 48 hours (SPID48) is the sum of the Pain Intensity Difference (PID) scores observed at 0.5 , 1, 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 hours post-dose. Pain Intensity scores at each timepoint are based on a 100 mm visual analog scale (VAS) from 0 = no pain to 100 = worst pain imaginable. PID is calculated as the timepoint score less the baseline pre-dose score (i.e. PID.5 = PI.5 - PI0).
SPID48 = the PID for each timepoint multiplied by a time weighting factor; which is the difference (in hours) between the PID observation and prior observation. SPID48 = PID.5*.5 + PID1*.5 + PID2*1 + PID3*1 + PID4*1 + PID6*2 +PID12*6 + PID18*6 +PID24*6 + PID30*6 + PID36*6 + PID42*6 + PID48*6. The maximum SPID48 value is 4,800 (assumes PI0 of 100 and a PI of 0 at all subsequent timepoints) with a midpoint SPID48 of 2,400 (PI0=50 and PI of 0 at all subsequent readings).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acurox 5/30mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone HCl 5mg/Niacin 30mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acurox 7.5/30</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oxycodone HCl 7.5mg/Niacin 30mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets every 6 hours for 48 hours</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acurox 5/30 mg</intervention_name>
    <description>2 tablets every 6 hours for 48 hours</description>
    <arm_group_label>Acurox 5/30mg</arm_group_label>
    <other_name>oxycodone/niacin 5/30mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acurox 7.5/30</intervention_name>
    <description>2 tablets every 6 hours for 48 hours</description>
    <arm_group_label>Acurox 7.5/30</arm_group_label>
    <other_name>oxycodone/niacin 7.5/30mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female at least 18 years of age

          -  For women of child-bearing potential: woman who is not pregnant and not nursing, and
             who is practicing an acceptable method of birth control

          -  Patient is scheduled to have a bunionectomy

          -  Patient must be willing to stay at the study site for at least 48 hours from the
             initial dose of study medication post-surgery

        Exclusion Criteria:

          -  Patient has a current disease or history of a disease that will impact the study or
             the patient's well-being

          -  Patient has used or intends to use any of the medications that are prohibited by the
             protocol

          -  Patient has a history of drug or alcohol abuse or dependence, or patient has a
             positive urine drug screen

          -  Patient is hypersensitive to any of the medications to be used in the study

          -  Patient has taken another investigational drug within 30 days prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2018</results_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>405 post-bunionectomy patients</recruitment_details>
      <pre_assignment_details>Subjects dose immediately post-surgery when pain intensity was equal to or greater than moderate. Dosed and followed for 48 hours.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>2 Tablets Every 6 Hours</description>
        </group>
        <group group_id="P2">
          <title>Acurox 5/30mg</title>
          <description>2x oxycodone 5mg/naicin 30mg every 6 hours</description>
        </group>
        <group group_id="P3">
          <title>Acurox 7.5/30mg</title>
          <description>2x oxycodone 7.5mg/naicin 30mg every 6 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>2x Placebo Tablets</description>
        </group>
        <group group_id="B2">
          <title>Acurox 5/30</title>
          <description>2x oxycodone/niacin 5/30mg tablets</description>
        </group>
        <group group_id="B3">
          <title>Acurox 7.5/30</title>
          <description>2x oxycodone/niacin 7.5/30mg tablets</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="134"/>
            <count group_id="B4" value="405"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="350"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.0" lower_limit="18" upper_limit="71"/>
                    <measurement group_id="B2" value="41.8" lower_limit="18" upper_limit="76"/>
                    <measurement group_id="B3" value="41.6" lower_limit="18" upper_limit="77"/>
                    <measurement group_id="B4" value="41.8" lower_limit="18" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="359"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SPID48</title>
        <description>Time weighted Sum of Pain Intensity Differences over the first 48 hours (SPID48) is the sum of the Pain Intensity Difference (PID) scores observed at 0.5 , 1, 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 hours post-dose. Pain Intensity scores at each timepoint are based on a 100 mm visual analog scale (VAS) from 0 = no pain to 100 = worst pain imaginable. PID is calculated as the timepoint score less the baseline pre-dose score (i.e. PID.5 = PI.5 - PI0).
SPID48 = the PID for each timepoint multiplied by a time weighting factor; which is the difference (in hours) between the PID observation and prior observation. SPID48 = PID.5*.5 + PID1*.5 + PID2*1 + PID3*1 + PID4*1 + PID6*2 +PID12*6 + PID18*6 +PID24*6 + PID30*6 + PID36*6 + PID42*6 + PID48*6. The maximum SPID48 value is 4,800 (assumes PI0 of 100 and a PI of 0 at all subsequent timepoints) with a midpoint SPID48 of 2,400 (PI0=50 and PI of 0 at all subsequent readings).</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Tablet</description>
          </group>
          <group group_id="O2">
            <title>Acurox 5/30</title>
            <description>oxycodone 5mg/niacin 30mg</description>
          </group>
          <group group_id="O3">
            <title>Acurox 7.5/30</title>
            <description>oxycodone 7.5mg/niacin 30mg</description>
          </group>
        </group_list>
        <measure>
          <title>SPID48</title>
          <description>Time weighted Sum of Pain Intensity Differences over the first 48 hours (SPID48) is the sum of the Pain Intensity Difference (PID) scores observed at 0.5 , 1, 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 hours post-dose. Pain Intensity scores at each timepoint are based on a 100 mm visual analog scale (VAS) from 0 = no pain to 100 = worst pain imaginable. PID is calculated as the timepoint score less the baseline pre-dose score (i.e. PID.5 = PI.5 - PI0).
SPID48 = the PID for each timepoint multiplied by a time weighting factor; which is the difference (in hours) between the PID observation and prior observation. SPID48 = PID.5*.5 + PID1*.5 + PID2*1 + PID3*1 + PID4*1 + PID6*2 +PID12*6 + PID18*6 +PID24*6 + PID30*6 + PID36*6 + PID42*6 + PID48*6. The maximum SPID48 value is 4,800 (assumes PI0 of 100 and a PI of 0 at all subsequent timepoints) with a midpoint SPID48 of 2,400 (PI0=50 and PI of 0 at all subsequent readings).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604.48" spread="1124.857"/>
                    <measurement group_id="O2" value="998.46" spread="1102.164"/>
                    <measurement group_id="O3" value="1224.97" spread="1128.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo Pill</description>
        </group>
        <group group_id="E2">
          <title>Acurox 5/30</title>
          <description>oxycodone 5mg/niacin 30mg</description>
        </group>
        <group group_id="E3">
          <title>Acurox 7.5/30</title>
          <description>oxycodone 7.5mg/niacin 30mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="136"/>
                <counts group_id="E2" events="68" subjects_affected="68" subjects_at_risk="135"/>
                <counts group_id="E3" events="83" subjects_affected="83" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="135"/>
                <counts group_id="E3" events="67" subjects_affected="67" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="135"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="135"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="135"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="135"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ron Spivey</name_or_title>
      <organization>Acura Pharma</organization>
      <phone>847-705-7709</phone>
      <email>rspivey@acurapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

